Booster vaccines protect hamsters with waning immunity from Delta VOC infection, disease, and transmission
Potts, K. G.; Noyce, R. S.; Gafuik, C.; John, C. M.; Todesco, H. M.; De Heuvel, E.; Favis, N.; Kelly, M. M.; Evans, D. H.; Mahoney, D. J.
Show abstract
Waning immunity to COVID-19 vaccination is associated with increased risk of breakthrough infection, especially with highly transmissible variants of concern (VOC). Booster vaccination generates rapid immune recall in humans, which real-world observational studies suggest protects against VOC infection and associated disease, and modeling studies suggest could mitigate community spread. We directly tested the impact of booster vaccination on protection against Delta VOC infection, disease, and transmission to naive cohorts in golden Syrian hamsters. Animals with waning immunity to bnt162b2 generated rapid immune recall and strong protection against upper- and lower-respiratory tract infection when boosted with bnt126b2, mRNA-1273 or AZD1222. Boosting with either mRNA vaccine generated moderate protection against lung inflammation and virus transmission to unvaccinated animals. Our data support booster vaccination as a tool to address emerging VOC in the COVID-19 pandemic. One-Sentence SummaryA booster vaccine delivered 9 months after primary bnt162b2 vaccination protects hamsters from Delta VOC infection, disease, and transmission.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Ending transmission of SARS-CoV-2: sterilizing immunity using an intranasal subunit vaccine 96%
- Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies 96%
- SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques 96%
Similar papers in this journal
- Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates 96%
- Deletion of immune evasion genes provides an effective vaccine design for tumor-associated herpesviruses 96%
- Durability of DNA-LNP and mRNA-LNP Vaccine-Induced Immunity Against SARS-CoV-2 XBB.1.5 96%
Similar papers in this journal
- Dissecting serotype-specific contributions to live oral cholera vaccine efficacy 95%
- A single-administration therapeutic interfering particle reduces SARS-CoV-2 viral shedding and pathogenesis in hamsters 94%
- Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques 93%
Similar papers in this journal
- Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model 95%
- Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines 94%
- Leveraging Pre-Vaccination Antibody Titers across Multiple Influenza H3N2 Variants to Forecast the Post-Vaccination Response 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.